Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference

October 20, 2021 8:30 AM

Presentation to highlight Mosaic's naturally-derived immuno-oncology candidate, MIE-101Intratumoral administration of MIE-101 activates immune cells to initiate potent, systemic and durable antitumor immunityNOVATO, CA / ACCESSWIRE / October 20, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies...

Read more

Applied UV's Systems Proven to Kill Candida Auris, an Emerging Multi-Drug-Resistant Fungus

October 19, 2021 9:00 AM

Candida Auris is a pathogenic disease commonly acquired in hospitals or long-term care facilitiesCenters for Disease Control and Prevention ("CDC") has stated that 30-60% of people with C. auris bloodstream infections die CDC currently considers Candidiasis as one of the most significant infectious diseases in the world today.Currently, there is no vaccine or preventative measures taken for C. auris for humansGrowing global scientific research...

Read more

Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

October 19, 2021 8:00 AM

Mortality reductions demonstrated across multiple patient groupsAdditional efficacy signals recorded in a broad range of mild to severe ARDS patientsCompany to focus on critically ill population for Phase 3TORONTO, ON / ACCESSWIRE / October 19, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced additional results from the Phase 2 part of an...

Read more

From Chronic to Curable? RHEACELL is Developing a Novel Cell-Therapy Agent for the Treatment of Chronic Venous Ulcers

October 19, 2021 3:30 AM

HEIDELBERG, GERMANY / ACCESSWIRE / October 19, 2021 / Heidelberg-based biopharmaceutical company is conducting a follow-up study with highly purified stem cells (AMESANAR (R) ) for the treatment of previously incurable chronic ulcers.Heidelberg, 19. October 2021 - More than 80,000 people in Germany suffer from chronic venous ulcers (CVU). Triggered by venous insufficiency, wounds and weeping ulcers can develop that may not heal for years....

Read more

Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis

October 18, 2021 4:01 PM

- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 -- DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 -- DMT310 demonstrated a 19.6% reduction from baseline in pruritus at Week 8 -- Phase 1b results support further investigation of DMT310 in psoriasis -SAN DIEGO, CA / ACCESSWIRE / October 18, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the...

Read more

dievini Explains Reasons for Changes in Shareholdings In CureVac Due To Legal Restructuring and Obligations Under a Share Program

October 18, 2021 2:10 AM

WALLDORF, GERMANY / ACCESSWIRE / October 18, 2021 / dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies, announced today that it and certain related parties filed on October 15, 2021, with the United States Securities and Exchange Commission an amendment to its Schedule 13D with respect to the common shares of CureVac.The...

Read more

Hemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom Laboratory

October 18, 2021 2:00 AM

LONDON, UK / ACCESSWIRE / October 18, 2021 / Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company ("Janus") for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of New York, adjacent to Columbia University and City College.The Company's new 10,000 rentable square feet lab will include two clean rooms purpose-built by Janus, allowing it to pursue...

Read more

Helix BioPharma Corp. Announces Delay of Annual Filings

October 15, 2021 8:00 PM

RICHMOND HILL, ON / ACCESSWIRE / October 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today that it anticipates the filing of its annual financial statements, management's discussion and analysis, annual information form and related officer certifications for the financial year ended July 31, 2021...

Read more

Apollo Endosurgery Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

October 15, 2021 4:05 PM

AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the closing of its previously announced underwritten public offering. Apollo sold 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional...

Read more

Fuse Science, Inc. Kustomeroo Enters into Partnership with Vanta for SOC 2 & HIPAA Compliance

October 15, 2021 10:00 AM

JACKSONVILLE, FL / ACCESSWIRE / October 15, 2021 / Fuse Science, Inc. (OTC PINK:DROP), Kustomeroo, provider of cloud video contact center solutions, is pleased to announce Kustomeroo has partnered with Vanta to achieve SOC 2 and HIPAA compliance. The partnership will assist in the process of obtaining SOC 2, HIPAA, and giving Kustomeroo the compliance reports needed to meet mandatory requirements large enterprise clients require. Kustomeroo is...

Read more

Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing

October 15, 2021 9:57 AM

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services of DBBMcKennon, LLC, a PCAOB Certified Public Accounting Firm. The Company has retained the firm to conduct an audit of its financials in order to become compliant with SEC reporting standards as it look towards its intended NASDAQ Capital Markets...

Read more

SUM, Superior Uptake Method, Launches First THC-V Product Line in Colorado

October 14, 2021 1:00 PM

SUM Microdose CURB and SUM Microdose CONTROL Bring THCV to COBOULDER, CO / ACCESSWIRE / October 14, 2021 / SUM, Superior Uptake Method, is a unique, fast acting, sugar-free, method to consume cannabis sold in Colorado dispensaries. Its SUM Microdose line of sublingual tablets dissolve under the tongue, bypassing the stomach and letting the cannabinoids avoid the slow and inhospitable journey of being metabolized through the GI tract. Absorbing...

Read more

Applied UV Announces Strategic Acquisition of Scientific Air Management to Accelerate its Growth and Strengthen its Portfolio of High Growth Air Purification Technologies

October 14, 2021 7:00 AM

Scientific Air is expected to contribute approximately $5-7 million in sales to Company's annualized revenues and be immediately accretive to Applied UV's earnings per shareContinues the acquisition strategy by Applied UV to acquire and consolidate air and pathogen disinfection industryCompany expects to be EBITDA positive during Q1 2022Product portfolio includes patented 24/7 large air volume, whole room UV-C pathogen killing...

Read more

Lexaria's Technology Proven to Deliver Oral THC More Effectively

October 13, 2021 11:00 AM

DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutesKELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral tetrahydrocannabinol ("THC") absorption study THC-A21-1 revealed that DehydraTECHTM-THC delivered via oral ingestion required only...

Read more

Hemogenyx Pharmaceuticals Announces CDX Licence Agreement

October 13, 2021 4:10 AM

LONDON, UK / ACCESSWIRE / October 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the "Agreement") with the global biopharmaceutical company Eli Lilly and Company ("Lilly"). Under this Agreement, Lilly grants the Company an exclusive worldwide licence to certain intellectual property developed by Lilly...

Read more

Apollo Endosurgery Announces Pricing of $65 Million Public Offering of Common Stock

October 12, 2021 11:40 PM

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the pricing of its previously announced underwritten public offering. Apollo is selling 8,400,000 shares of its common stock at a public offering price of $7.75 per share for gross proceeds of approximately $65 million, before deducting...

Read more

Apollo Endosurgery Announces Commencement of Public Offering of Common Stock

October 12, 2021 4:01 PM

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock is being offered by Apollo. In addition, Apollo expects to grant the underwriters a 30-day option to purchase additional...

Read more

Black Bird Biotech Announces Recent In-Field Use of MiteXstreamTM Have Reveled the Potential of MiteXstreamTM As a Biopesticide with Repellent Qualities

October 12, 2021 8:30 AM

FLOWER MOUND, TX / ACCESSWIRE / October 12, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, announced today that, during recent in-field use of MiteXstreamTM, it has become apparent that MiteXstreamTM is effective in repelling certain pests, including grasshoppers and potato bugs, from plants. With EPA biopesticide certification already in hand, this recent result, which is still to be...

Read more

Rain Bio Appoints Gary Sternberg, MD, MBA as Acting Chief Executive Officer

October 12, 2021 8:00 AM

RALEIGH, NC / ACCESSWIRE / October 12, 2021 / Today, RainBio Inc., a leading developer of novel gene therapies for blinding corneal diseases, announced the appointment of Gary Sternberg, MD, MBA, as its acting chief executive officer. Dr. Sternberg, who has served in various leadership positions in biotech and eye care, brings over 20 years of industry R&D experience to the role."We're thrilled to welcome Dr. Sternberg to RainBio and look...

Read more

Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates

October 12, 2021 8:00 AM

Presentation detailed the Company's COVID-19 vaccine candidates that generated antibodies that neutralized SARS-CoV-2 infection of human cellsVaccine candidates hold potential for rapid response to regions that may lack the infrastructure to support traditional temperature-sensitive vaccinesNOVATO, CA / ACCESSWIRE / October 12, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology...

Read more